  Regulating the upstream of the cytokines production could be a promising
strategy to the treatment of COVID-19. We suggest to pay more attention to the
dysregulated IFN-I production in COVID-19 and to considerate cGAS, ALK and
STING as potential therapeutic targets preventing cytokine storm. Approved
drugs like suramin and ALK inhibitors are worthy of clinical trials.
